Drugs / EGFRBi armed ATC Infusions
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01420874 | Aug 2011 → Oct 2020 | colon carcinoma, malignant pancreatic neoplasm | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EGFRBi armed ATC Infusions | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01420874 ↗ |
| Known as | BATs | “Purpose This was a phase I/II adoptive T cell trial in 7 locally advanced and metastatic pancreatic cancer patients using 3-8 infusions of anti-CD3 x anti-EGFR bispecific...” PMID 32939319 ↗ Jun 2020 |
| Modality | Cell therapy | “adoptive T cell trial” PMID 32939319 ↗ Jun 2020 |
| Route | Intravenous | “Armed ATC will be infused intravenously (IV)” NCT01420874 ↗ |
| Target | EGFR | “anti-CD3 x anti-EGFR bispecific antibody armed activated T cells” PMID 32939319 ↗ Jun 2020 |